Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsNon-Current Deferred Tax LiabilityOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Neuphoria Therapeutics (NEUP) Non-Current Assets (2022 - 2025)

Neuphoria Therapeutics (NEUP) has disclosed Non-Current Assets for 4 consecutive years, with $13.2 million as the latest value for Q4 2025.

  • On a quarterly basis, Non-Current Assets fell 4.05% to $13.2 million in Q4 2025 year-over-year; TTM through Dec 2025 was $53.8 million, a N/A change, with the full-year FY2025 number at $13.5 million, changed N/A from a year prior.
  • Non-Current Assets was $13.2 million for Q4 2025 at Neuphoria Therapeutics, down from $13.4 million in the prior quarter.
  • In the past five years, Non-Current Assets ranged from a high of $16.8 million in Q2 2022 to a low of $13.2 million in Q4 2025.
  • A 4-year average of $14.3 million and a median of $13.7 million in 2024 define the central range for Non-Current Assets.
  • Peak YoY movement for Non-Current Assets: dropped 9.04% in 2023, then decreased 4.05% in 2025.
  • Neuphoria Therapeutics' Non-Current Assets stood at $16.8 million in 2022, then fell by 9.04% to $15.3 million in 2023, then dropped by 10.07% to $13.8 million in 2024, then dropped by 4.05% to $13.2 million in 2025.
  • Per Business Quant, the three most recent readings for NEUP's Non-Current Assets are $13.2 million (Q4 2025), $13.4 million (Q3 2025), and $13.5 million (Q2 2025).